SXTP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
207.9K
+28.3%
162.1K
-48.8%
316.4K
-40.1%
528.6K
+71.7%
307.9K
Cost of Revenue
151.1K
+76.3%
85.7K
-29.0%
120.7K
-77.6%
537.7K
+974.3%
50.1K
Gross Profit
56.8K
-25.6%
76.4K
-61.0%
195.7K
+2243.9%
-9128
-103.5%
257.8K
Operating Expenses
2.3M
+7.2%
2.2M
+2.8%
2.1M
-8.8%
2.3M
+24.3%
1.9M
R&D
598.7K
+112.7%
281.5K
-55.9%
638.9K
-21.1%
809.8K
+249.2%
231.9K
SG&A
1.7M
-8.5%
1.9M
+28.2%
1.5M
-2.2%
1.5M
-7.7%
1.6M
Operating Income
-2271102
-8.4%
-2094961
-9.3%
-1917351
+17.6%
-2325525
-44.8%
-1606328
EBITDA
-2307894
-14.0%
-2024518
-17.9%
-1717313
+25.4%
-2302695
-39.4%
-1651313
Net Income
-2265586
-8.4%
-2090155
-45.2%
-1439058
+37.9%
-2317036
-33.6%
-1734930
EPS (Basic)
$-0.90
+29.7%
$-1.28
$-2.64
+47.3%
$-5.01
EPS (Diluted)
$-0.90
+29.7%
$-1.28
$-2.64
+47.3%
$-5.01
Shares (Diluted)
2.7M
+53.8%
1.7M
918.9K
+149.5%
368.3K
60 Degrees Pharmaceuticals (SXTP) — Financials